comparemela.com

Latest Breaking News On - Direct lytic agents - Page 1 : comparemela.com

ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit

ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit YONKERS, N.Y., April 15, 2021 (GLOBE NEWSWIRE) ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research, will virtually present the Company’s anti-infective portfolio and platform technology of DLAs in the session on “Advancing Clinical Superiority of Anti-Infectives to Drive Commercial Success.” Dr. Cassino’s presentation will focus on the powerful antimicrobial attributes of DLAs which underpin the potential for superior clinical outcomes for serious, life-threatening, and critically underserved infections and the Company’s novel development pathway exp

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.